BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $4,969,000 | +13.0% | 499,889 | +3.2% | 0.01% | 0.0% |
| Q2 2022 | $4,399,000 | -20.0% | 484,477 | -10.6% | 0.01% | +25.0% |
| Q1 2022 | $5,500,000 | -32.7% | 541,891 | +10.7% | 0.00% | 0.0% |
| Q4 2021 | $8,169,000 | -62.6% | 489,721 | +5.1% | 0.00% | -63.6% |
| Q3 2021 | $21,835,000 | -14.7% | 465,876 | +11.0% | 0.01% | -8.3% |
| Q2 2021 | $25,597,000 | +32.9% | 419,892 | +34.3% | 0.01% | +9.1% |
| Q1 2021 | $19,259,000 | +128.5% | 312,645 | +163.8% | 0.01% | +120.0% |
| Q4 2020 | $8,429,000 | +271.5% | 118,532 | +96.0% | 0.01% | +150.0% |
| Q3 2020 | $2,269,000 | +1100.5% | 60,469 | +941.0% | 0.00% | – |
| Q2 2020 | $189,000 | +142.3% | 5,809 | +115.1% | 0.00% | – |
| Q1 2020 | $78,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |